Moutsopoulos et al. [14] found an elevated IL-23 (interleukin-23) and IL-17 (interleukin-17) signature at inflamed sites and treated one adult LAD I patient with the monoclonal anti-IL12/IL-23 antibody ustekinumab, successfully ameliorating his inflammatory symptoms without exacerbating his infections. This evidence concerns the gene IL23A and infection.